

Edgar Filing: EXEGENICS INC - Form 8-K

EXEGENICS INC  
Form 8-K  
July 16, 2003

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K  
CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) July 16, 2003  
-----

EXEGENICS INC.

(Exact name of registrant as specified in its charter)

Delaware	00-26078	75-2402409
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

2110 Research Row  
Dallas, Texas 75235

(Address of principal executive  
offices including zip code)

(214) 358-2000

(Registrant's telephone number,  
including area code)

N.A.

----

(Former name or former address, if changed since last report)

ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE.

On July 16, 2003, eXegenics issued a press release announcing that eXegenics and AVI BioPharma, Inc. have entered into an Agreement and Plan of Merger. A copy of the press release is filed herewith as Exhibit 99.1 and incorporated herein by reference. A copy of the Agreement and Plan of Merger is filed herewith as Exhibit 2.1 and incorporated herein by reference.

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.

(c) The following exhibits are furnished with this report:

Exhibit Number	Description
2.1	Agreement and Plan of Merger, entered into as of July 16, 2003, among AVI BioPharma, Inc., Elk Acquisition, Inc. and eXegenics Inc.

## Edgar Filing: EXEGENICS INC - Form 8-K

99.1

Press Release from eXegenics Inc., dated July 16, 2003.

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EXEGENICS INC.  
(Registrant)

Dated: July 16, 2003

By: /s/ Ronald L. Goode

-----  
Ronald L. Goode  
Chairman, President and Chief Executive Officer

### INDEX TO EXHIBITS

Exhibit Number	Description
-----	-----
2.1	Agreement and Plan of Merger, entered into as of July 16, 2003, among AVI BioPharma, Inc., Elk Acquisition, Inc. and eXegenics Inc.
99.1	Press Release from eXegenics Inc., dated July 16, 2003.